Compare ZDGE & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | ATNM |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 33.9M |
| IPO Year | 2016 | 2013 |
| Metric | ZDGE | ATNM |
|---|---|---|
| Price | $3.12 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 63.6K | ★ 103.6K |
| Earning Date | 06-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 73.85 | 14.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | $90,000.00 |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $2.21 | $0.95 |
| 52 Week High | $4.70 | $1.95 |
| Indicator | ZDGE | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 38.48 |
| Support Level | $2.87 | $1.02 |
| Resistance Level | $3.43 | $1.27 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 79.17 | 2.08 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.